LMCD1 Antibody

Introduction to LMCD1 and Its Antibody

LMCD1 is a member of the LIM protein family, characterized by an N-terminal cysteine-rich region, two C-terminal LIM domains, and a central PET domain . It functions as a transcriptional cofactor, interacting with factors like GATA6 and NFATc1 to regulate gene expression in cardiac, lung, and vascular tissues . LMCD1 antibodies enable detection and functional analysis of this protein in research settings, including Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) .

Vascular Remodeling and Species-Specific Roles

LMCD1 antibodies have elucidated species-specific regulatory mechanisms in vascular smooth muscle cells (VSMCs):

• Human VSMCs: LMCD1 acts as an activator of E2F1 and NFATc1, promoting CDC6 (cell cycle progression) and IL-33 (pro-inflammatory cytokine) expression, driving proliferation and migration .

• Mouse VSMCs: LMCD1 functions as a repressor of E2F1/NFATc1, with thrombin-induced myristoylation abolishing repression .

• Clinical Relevance: Increased LMCD1 expression correlates with human stenotic arteries, while reduced levels are observed in mouse neointimal lesions .

Fibrosis and Scleroderma

LMCD1 antibodies identified LMCD1 as a profibrotic factor in scleroderma-associated interstitial lung disease (SSc-ILD):

• Mechanisms: LMCD1 depletion reduces TGFβ-induced collagen I, fibronectin, and SMA expression in fibroblasts .

• Localization: LMCD1 co-localizes with SMA in fibrotic lung tissue, indicating a role in myofibroblast activation .

Osteogenic Differentiation

In human bone marrow stromal cells (BMSCs), LMCD1 knockdown inhibits osteogenic markers (e.g., COL1A1, RUNX2), while overexpression enhances mineralization .

Western Blot Protocol (Proteintech 67834-1-Ig)

1. Sample Preparation: Lyse cells in RIPA buffer, resolve proteins via SDS-PAGE.

2. Transfer: Transfer to PVDF membrane, block with 5% BSA.

3. Detection: Incubate with 1:1,000 diluted antibody, followed by HRP-conjugated secondary antibody .

Immunofluorescence Protocol (CL488-67834)

1. Fixation: 4% PFA for 10–15 minutes.

2. Permeabilization: 0.1% Triton X-100.

3. Staining: Incubate with 1:50 diluted antibody, visualize via fluorescence microscopy .